While multiple pharmaceutical companies look for vaccines to fight against coronavirus, others are getting into the business of reducing symptoms of the disease that often cause hospitalization.
Pharmaceutical giant Eli Lilly announced significant progress this week with its antibody treatment, called LY-CoV555, which appears to reduce the number of COVID-19 patients admitted for care.
"We believe that the data that we generated could be a real turning point in the fight against the coronavirus," said Andrew Adams, vice president of new therapeutic modalities and COVID-19 research.
"This is the first time we have a real understanding of the virus in the outpatient setting," he told Cheddar. "This data represents, really, a first in terms of potential options for patients in the future should this data bear out in bigger studies."
The drugmaker has also conducted a successful round of trials using rheumatoid arthritis drug baricitinib and antiviral medication remdesivir to reduce the number of days a patient requires hospitalization
When comparing the two options, Adams said deciding which treatment better suits patients depends on how long an individual has been living with the virus. People that have been hospitalized as a result of COVID-19 are more likely to have more internal damage "because of the inflammatory reaction to the virus" and likely benefit more from the baricitinib and remdesivir cocktail.
"In the prophylactic setting, for example, in the nursing homes, you likely wouldn't see the same kind of benefit as you'd see in a hospitalized setting because the immune system isn't as involved yet in the symptoms of the disease," he explained.
When it comes to costs, Eli Lilly says it's keeping families in mind, especially as medical bills and other expenses pile up amid the pandemic. Adams said the company is also working with physicians and patients to get a better understanding of their needs.
"The key guiding principle from our leadership team here at Lilly is making sure that patients who need access to our medicines in the coronavirus space get their access — around the globe, not just here in the U.S.," Adams said.
The KC-46 was to be the ideal candidate for a fixed-price development program. Instead, it has cost Boeing billions, and made industry wary of such deals.
Dave Long, CEO and Co-Founder of Orangetheory Fitness joins Cheddar to chat trends in the industry for 2024. He updates us on the company's plans to expand and what the state of the economy has meant for business.
One of the world's largest renewable energy developers will be getting hundreds of wind turbines from General Electric spinoff GE Vernova as part of a record equipment order and long-term service deal.
A moon landing attempt by a private US company appears doomed because of a fuel leak on the newly launched spacecraft. Astrobotic Technology managed to orient the lander toward the sun Monday so its solar panel could capture sunlight and charge its onboard battery.
Treasury Secretary Janet Yellen has announced that 100,000 businesses have signed up for a new database that collects ownership information intended to help unmask shell company owners. Yellen says the database will send the message that “the United States is not a haven for dirty money.”
A new version of the federal student aid application known as the FAFSA is available for the 2024-2025 school year, but only on a limited basis as the U.S. Department of Education works on a redesign meant to make it easier to apply.
A steep budget deficit caused by plummeting tax revenues and escalating school voucher costs will be in focus Monday as Democratic Gov. Katie Hobbs and the Republican-controlled Arizona Legislature return for a new session at the state Capitol.
The first U.S. lunar lander in more than 50 years is on its way to the moon. The private lander from Astrobotic Technology blasted off Monday from Cape Canaveral, Florida, catching a ride on United Launch Alliance's brand new rocket Vulcan.
Global prices for food commodities like grain and vegetable oil fell last year from record highs in 2022, when Russia’s war in Ukraine, drought and other factors helped worsen hunger worldwide, the U.N. Food and Agriculture Organization said Friday.
